S&P Futures
5,885.25 -11.00 (-0.19%) Dow Futures
43,113.00 -64.00 (-0.15%) Nasdaq Futures
20,466.50 -53.00 (-0.26%) Russell 2000 Futures
2,249.00 -6.50 (-0.29%) Crude Oil
70.43 -0.13 (-0.18%) Gold
2,748.50 +9.60 (+0.35%)
Sun Pharmaceutical Industries Limited (SUNPHARMA.NS)
| Previous Close | 1,897.00 |
| Open | 1,892.00 |
| Bid | 1,901.95 x 0 |
| Ask | 1,903.00 x 0 |
| Day's Range | 1,881.00 - 1,906.00 |
| 52 Week Range | 1,068.35 - 1,960.35 |
| Volume | |
| Avg. Volume | 2,088,255 |
| Market Cap | 4.564T |
| Beta (5Y Monthly) | 0.55 |
| PE Ratio (TTM) | 43.87 |
| EPS (TTM) | 43.36 |
| Earnings Date | Oct 28, 2024 |
| Forward Dividend & Yield | 13.50 (0.71%) |
| Ex-Dividend Date | Jul 12, 2024 |
| 1y Target Est | 829.22 |
ReutersIndia flags quality issues with some widely used antacids and paracetamol
BENGALURU (Reuters) -India's drug regulator has found more than 50 drugs, including some batches of widely used antacids and paracetamol, to be substandard or fake, according to government documents. The regulator, Central Drugs Standard Control Organisation, releases a monthly list of substandard or fake medicines sold in the country after routine tests across the country by multiple agencies. The regulator found some drugs as "not of standard quality", including a batch each of Alkem Laboratories' popular antacid Pan-D, Hetero's anti-infective Cepodem and Shelcal, a vitamin and calcium tablet brand made by privately-owned Pure & Cure Healthcare, and several antibiotics, according to the lists for August.
Pharmaceutical TechnologySun Pharma and Moebius gain FDA fast track for osteoarthritis drug
MM-II reduces joint friction and wear, thereby alleviating pain.
